Mirvetuximab soravtansine (also known as Elahere) is the first new drug to be approved for hard-to-treat ovarian cancer in over 20 years.
- Professor and Head of the School of Life Sciences, Anglia Ruskin University
Contact Steve for
- General
- Media request
- Speaking request
- Consulting / Advising
- Research collaboration
- Research supervision
- Article Feed
- ORCID
- Joined
